Brokerages Set Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Target Price at $259.06

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) have been assigned a consensus rating of “Moderate Buy” from the twenty analysts that are currently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $272.7368.

JAZZ has been the subject of a number of research reports. Needham & Company LLC boosted their price target on shares of Jazz Pharmaceuticals from $282.00 to $292.00 and gave the company a “buy” rating in a research report on Tuesday. Royal Bank Of Canada raised their price objective on Jazz Pharmaceuticals from $195.00 to $258.00 and gave the stock an “outperform” rating in a report on Wednesday, May 6th. Bank of America boosted their target price on Jazz Pharmaceuticals from $281.00 to $307.00 and gave the company a “buy” rating in a report on Wednesday, June 10th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $287.00 target price on shares of Jazz Pharmaceuticals in a research report on Tuesday. Finally, Weiss Ratings raised Jazz Pharmaceuticals from a “hold (c-)” rating to a “buy (b-)” rating in a research report on Tuesday.

Jazz Pharmaceuticals News Summary

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz reported second-quarter revenue of $1.21 billion, ahead of the $1.11 billion consensus estimate and up 15.5% year over year. Management raised its 2026 revenue forecast to $4.60 billion-$4.75 billion, citing strength in its oncology and neuroscience businesses. JAZZ Q2 Earnings Miss, Sales Beat, Stock Jumps on Raised 2026 View
• Positive Sentiment: The company’s oxybate franchise, led by Xywav, continues to grow at a double-digit rate despite the launch of generic Xyrem, easing concerns about generic competition and supporting the improved guidance. Jazz Pharmaceuticals’ Re-Rating Story Has Legs
• Positive Sentiment: Multiple analysts raised their price targets following the results. Needham lifted its target to $292 and maintained a buy rating, while Morgan Stanley and Robert W. Baird raised targets to $280 with overweight and outperform ratings, respectively. JPMorgan also raised its target to $276 and maintained overweight ratings. Needham Raises Jazz Pharmaceuticals Price Target
• Positive Sentiment: Investors are also watching zanidatamab, marketed as Ziihera. A potential first-line gastroesophageal adenocarcinoma approval, with an FDA decision expected August 25, could create a significant new revenue stream and accelerate growth. Jazz Forecasts 2026 Revenue Ahead of Zanidatamab FDA Decision
• Neutral Sentiment: Second-quarter adjusted EPS was $5.71, below the $6.18 consensus estimate. The revenue beat and raised outlook outweighed the earnings miss in the market’s initial reaction, but profitability remains an area to monitor.
• Negative Sentiment: Jazz said it will withdraw Zepzelca from the FDA’s accelerated-approval pathway for second-line small-cell lung cancer, removing a potential regulatory catalyst and highlighting pressure on that product. Jazz to Withdraw Zepzelca FDA Application
• Negative Sentiment: Director Bruce C. Cozadd sold 6,000 shares worth approximately $1.52 million under a pre-arranged Rule 10b5-1 plan. Because the sale reduced his holdings by only 1.64% and was planned in advance, it is a limited negative signal rather than a clear change in insider conviction. Jazz Pharmaceuticals Insider Transaction Filing

Insiders Place Their Bets

In related news, Director Heather Ann Mcsharry sold 2,000 shares of the company’s stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $241.00, for a total value of $482,000.00. Following the completion of the sale, the director owned 18,449 shares in the company, valued at $4,446,209. This represents a 9.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bruce C. Cozadd sold 6,000 shares of the stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $252.98, for a total transaction of $1,517,880.00. Following the sale, the director owned 360,682 shares of the company’s stock, valued at approximately $91,245,332.36. This represents a 1.64% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 19,098 shares of company stock worth $4,649,786. Corporate insiders own 4.10% of the company’s stock.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. USA Financial Formulas acquired a new position in Jazz Pharmaceuticals in the 1st quarter valued at about $25,000. LRI Investments LLC acquired a new stake in Jazz Pharmaceuticals during the 4th quarter worth approximately $38,000. Thurston Springer Miller Herd & Titak Inc. purchased a new position in shares of Jazz Pharmaceuticals in the 2nd quarter valued at approximately $61,000. Westpac Banking Corp purchased a new position in shares of Jazz Pharmaceuticals in the 1st quarter valued at approximately $51,000. Finally, Leonteq Securities AG acquired a new position in shares of Jazz Pharmaceuticals in the fourth quarter valued at approximately $50,000. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

Shares of Jazz Pharmaceuticals stock opened at $261.57 on Friday. The company has a quick ratio of 1.85, a current ratio of 1.78 and a debt-to-equity ratio of 0.69. Jazz Pharmaceuticals has a 52 week low of $105.00 and a 52 week high of $265.05. The firm’s 50 day moving average is $240.46 and its two-hundred day moving average is $208.57. The firm has a market capitalization of $16.98 billion, a P/E ratio of 18.04, a P/E/G ratio of 0.23 and a beta of 0.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share for the quarter, missing the consensus estimate of $6.18 by ($0.47). Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%.The company had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.11 billion. During the same quarter in the prior year, the firm posted ($8.25) EPS. The firm’s quarterly revenue was up 15.5% compared to the same quarter last year. Research analysts forecast that Jazz Pharmaceuticals will post 21.9 EPS for the current fiscal year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.